Best Life Sciences Companies in Hong Kong, China
The 106 best Life Sciences companies in Hong Kong, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Ascentage Pharma.
Our analysis of 50 Life Sciences companies
$5.7b in tracked funding; 40% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Hong Kong
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Casigen Pharma ERRα targeted small molecule drugs for type 2 diabetes | $4M | — | Deadpooled | Stephen Lee CEO | — | — | — | — |
| 2 | Abida Medical Provider of breast cancer screening solutions | — | — | Deadpooled | Alec Nicol CEO | — | — | — | — |
| 3 | Acticule The developer of therapeutics for infectious disease | — | — | Deadpooled | Richard Kao Founder | — | — | — | — |
| 4 | Add Care Offers wearable for blood glucose monitoring | — | — | Unfunded | He Yaowei CEO | 4 | — | — | — |
| 5 | AlphaRx Developer of therapies for treating inflammation, stroke, and pneumonia | — | — | Public | Michael Lee Founder & CEO | — | — | — | — |
| 6 | Apotechary Wearables for vital signs monitoring | — | — | Deadpooled | Kerwin Kong Co-Founder & CFO | — | — | — | — |
| 7 | Arbele Developer of therapeutic solutions for the treatment of cancers | — | — | Funding Raised | John Luk Chairman & Founder | 21 | WebflowMicrosoft 365jQuery+8 | 22 patents Patents concentrated in chemistry & materials | — |
| 8 | Asia Microbiota Bank Provider of bio bank of fecal microbiota | — | — | Unfunded | Noel Krive Co-Founder | — | WordPressMySQLPHP+18 | — | — |
Top 12 Life Sciences companies in Hong Kong
#1
Public · Hong Kong, Hong Kong · founded 2009 · 400 employees$67.7Mraised▾
Online platform for genetic and diagnostic health testing that helps identify health risks. The company has developed Covid-19 PCR tests and rapid test kits and analyzes the samples by using whole-genome sequencing technology. Also, it has developed a DNA screening test for detecting colon cancer.
- Oct 2025Post IPO$48M
- Jul 2024Post IPO—
- Sep 2020Series B$15M
- Oct 2017Series B$40M
#2
Seed · Hong Kong, Hong Kong · founded 2021$10Mraised▾
Provider of gene editing-based solutions for genetic diseases. The company develops precision gene-editing technology and develop a pipeline of programmable gene therapy products.
- Sep 2024Seed—
- Apr 2024Seed$10M
#3
Public · Hong Kong, Hong Kong · founded 2005 · 1990 employees$215Mraised▾
Developer of immunotherapies for the treatment of cancer and immunological diseases. The company's drugs include Savolitinib, Surufatinib, Fruquintinib, HMPL-523, HMPL-689, HMPL-453, HMPL-306, HMPL-295, and Eptinib. These drugs can be used alone or in combination with other drugs. These drugs are potent oral inhibitors of vascular endothelial growth factor receptors.
- Mar 2022Post IPO$15M
- Apr 2021Post IPO$100M
- Jun 2020Post IPO$100M
#4
Public · Hong Kong, Hong Kong · founded 2012 · 50 employees$12.8Mraised▾
Developer of radiation-free 3D ultrasound scoliosis assessment. It offers a portable device Scolioscan Air with a cloud-based ScolioNet software for 3D analysis of the spinal images.
- Mar 2024Seed$5.5M
- Apr 2023Seed—
#5
Series A · Hong Kong, Hong Kong · founded 2021$10Mraised▾
Developer of robotic instruments for endoscopic surgery. The company provides clinicians with the next generation of minimally invasive instruments to assist in manual procedures of the targeted market such as gastrointestinal and bladder surgeries.
- Mar 2024Series A$10M
#6
Public · Hong Kong, Hong Kong · founded 2000 · 845 employees$200Mraised▾
Chi-Med (also known as Hutchison China Meditech, a part of CK Hutchison holdings) is a public biopharma company developing therapeutics in Oncology and Immune Diseases. The company has 7 clinical-stage drug candidates in its pipeline, 5 of which already achieved proof-of-concept. The company owns 4 of the candidates and has partnerships on the others with AstraZeneca, Eli Lilly and Nestle Health Science. Some of its most advanced clinical candidates include - HMPL-004 (Phase III drug targeting TNF alpha to treat Ulcerative Colitis; Also in development for Crohn's Disease; Being co-developed with Nestle), Fruquintinib (Phase III drug targeting VEGF to treat Colorectal Cancer; Other indications NSCLC and Gastric Cancer; Being codeveloped with Lilly) and Savolitinib (Phase II drug targeting c-Met to treat Papillary renal cell carcinoma; Also in development against NSCLC and Gastric Cancer; Being co-developed by Astra Zeneca).
- Nov 2020Post IPO$100M
- Jun 2020Post IPO$100M
#7
Series C · Hong Kong, Hong Kong · founded 2009 · 565 employees$237.5Mraised▾
Developer of small molecules drugs for the treatment of cancers. Its drug pipeline includes AT101, a pan Bcl-2 inhibitor for non-small cell lung cancer, HQP 8361, a C-met inhibitor for solid tumors, APG-1387, an IAP inhibitor for solid tumors, HQP1351, a Bcr- Abl kinase small-molecule inhibitor for the treatment of chronic myeloid leukemia. The company also has several preclinical discovery programs targeting key oncogenic drivers in human cancer.
- Jul 2018Series C$150M
- Dec 2016Series B$72M
- Aug 2015Series A$15.5M
#8
Series A · Sha Tin, Hong Kong · founded 2015$12Mraised▾
Developer of DNA vaccines and immunotherapies for multiple disorders. It offers a PD-1-enhanced DNA vaccine and Anti-Δ42PD1 antibody immune blockade technology platforms for developing therapeutics for multiple cancers, and inflammatory, and infectious diseases.
- Jul 2023Series A$12M
#9
Series B · Hong Kong, Hong Kong · founded 2014$60Mraised▾
CircleDNA is an internet first diagnostics lab for genetic tests. It offers genetic tests for personalized and proactive health. The company offers test kits for cardiovascular diseases, psychiatric disorders, pain management, miscellaneous common drugs, drug allergies, diabetes, among others. The company uses the technology for Whole Exome Sequencing for detection.
- Sep 2020Series B$15M
#10
Acquired · Hong Kong, Hong Kong · founded 2003 · 1202 employees$115Mraised▾
Provider of biobanking services for umbilical cord blood stem cells. The company provides umbilical cord blood storage services for parents to save cord blood stem cells.
- Apr 2012Post IPO$65M
- 2007PE—
- Post IPO$50M
#11
Seed · Hong Kong, Hong Kong · founded 2013$9Mraised▾
Developer of AI-powered disinfection and sterilization devices. The company focuses on developing next-generation cleaning, disinfection, and sterilization technology infrastructure for public spaces and hospital environments. The company's product Whiz Gambit is an AI-based disinfectant robot for hospital operators and infectious diseases.
- Apr 2022Seed$9M
#12
Series B · Tsim Sha Tsui, Hong Kong · founded 2018$28.1Mraised▾
Gene Tech is a provider of genetic testing services. The company uses next-generation gene sequencing (NGS) and full exome sequencing (WES) technology for genetic tests and sequence analysis. Service offerings include consultant interpretation report, provides practical solutions to problems, confidential customer information, order tests and manage results using the online platform.
- Sep 2019Series B$28.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.